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Identity 
Other names: MIRN145, miR-145, miRNA145 




miR-145 is located on chromosome 5 (5q32-33) within 
a 4.09 kb region (miRBase).  
The pri-microRNA structure of miR-145 has not been 
identified, yet it is suggested that it co-transcribed with 
miR-143.  
This gene has been implicated as both tumor and 
metastasis suppressor in multiple tumor types 
(Sachdeva and Mo, 2010a). 
Transcription 
miR-145 is transcribed by RNA pol-II into pri- 
miRNA sequence, which is first processed to pre-
miRNA (~88 bp long) involving RNA cutting and 
exporting, and finally to mature miR-145. miR-145 is a 
p53-regulated gene.  
Several reports suggest that miR-145 can be induced 
transcriptionally by p53 in response to stress such as 
serum starvation or anticancer drugs (Sachdeva et al., 
2009; Spizzo et al., 2010).  
Interestingly, another report showed a novel 
mechanism of posttranscriptional regulation of miR-
145 that occurs via p53-mediated RNA processing 
(Suzuki et al., 2009).  
Recently, a study demonstrates that activated Ras can 
suppress miR-143/145 cluster through Ras-responsive 
element-binding protein (RREB1), which represses the 
miR-143/145 promoter (Kent et al., 2010). 
Pseudogene 
There is no pseudogene reported for this gene. 
 
Figure 1: A) Genomic localization of miR-145 gene on chromosome 5q32. B) Stem-loop structure of miR-145 (Red: mature miR-145 
sequence). 












No mutations have been found in mature miR-145 
sequence; however, a study suggests that OVCAR8 
(ovary) and NCI-H727 (lung) cells harbor mutations in 
pri-miR-145, i.e., C-133A/pri-microRNA/homozygous 
and G-5R (G/A)/pri-microRNA/heterozygous, 
respectively. Yet, these mutations do not have any 





Downregulation of miR-145 has been found in cancers 
of many tissue types including colon, breast, prostate, 
pancreas, etc. (Sachdeva et al., 2009; Bandres et al., 
2006; Michael et al., 2003). For example, in situ 
hybridization detected accumulation of miR-145 in 
normal colon epithelia with no signal from 
adenocarcinomas cells. Loss of miR-145 in various 
tumors suggests its role as a tumor suppressor. In fact, 
miR-145 has been well documented as a tumor 
suppressor gene in multiple tumor types because of its 
anti-proliferative and pro-apoptotic effects. It is shown 
that miR-145 can negatively regulate multiple 
oncogenes such as MYC, Kras, IRS-1, ERK5, etc. 
involved in cell proliferation and survival (Sachdeva et 




Several reports suggest that miR-145 is a suppressor of 
metastasis. For example, mir-145 negatively regulates 
MUC1 and suppresses invasion and metastasis of the 
breast cancer cells (Sachdeva and Mo, 2010b). Similar 
findings in prostate cancer and in gliomas have further 
confirmed the role of miR-145 as a metastasis 
suppressor by targeting genes including FASCN1 and 
SOX2, respectively (Fang et al., 2011; Watahiki et al., 
2011; Leite et al., 2011). 
Stem cells and differentiation 
Note 
A study has shown that miR-145 is induced during 
differentiation, and it directly silences the stem cell self 
renewal and pluripotency program by suppressing 
multiple pluripotent genes such as OCT4, SOX2 and 
KLF4 (Xu et al., 2009). 
 
Vascular smooth muscle cells 
Note 
The role of miR-145 in differentiation of vascular 
smooth muscle cell (VSMC) has been recently 
investigated. A report demonstrated that miR-145 is the 
most enriched microRNA in arteries and its expression 
is significantly downregulated in vascular walls with 
neointimal lesions (Chen et al., 2004). Similarly, 
another group, using transgenic mouse model with 
miR-145 promoter fused to β-galactosidase gene, found 
that miR-145 is cardiac-specific and smooth-muscle 
specific microRNA regulated by serum response factor, 
myocardin and Nkx2-5 (NK2 transcription factor 
related, locus 5) (Cordes et al., 2009). Further evidence 
from the miR-43/miR-145 KO rats suggests that this 
microRNA cluster is expressed mostly in the SMC 
compartment in vessels and SMC-containing organs 
and their loss induces an incomplete differentiation of 
VSMCs (Elia et al., 2009). 
5q syndrome 
Note 
A comprehensive study using clinical samples 
combined with mouse models have found that deletion 
of chromosome 5q correlates with loss of two miRNAs 
that are abundant in hematopoietic stem/progenitor 
cells (HSPCs), miR-145 and miR-146a. In addition, 
they observed that miR-145 is highly expressed in 
primitive lin- (mouse) and CD34+ (human) bone 
marrow cells than committed cells and stable 
knockdown of miR-145 in these cells in mouse marrow 
results in 5-q syndrome (Starczynowski et al., 2010). 
Similar work from another group in patients with del 
(5q) have decreased expression of miR-145 and 
increased expression of Fli-1 (Kumar et al., 2011). 
They found that miR-145 functions through repression 
of Fli-1, a megakaryocyte and erythroid regulatory 
transcription factor and thus, cells lacking miR-145 
have impaired megakaryocyte and erythroid 
differentiation. 
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